Brings Strong Industry and Executive Level Experience to Company
FT. MYERS, Fla., March 16 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (OTC Bulletin Board: NGNM), a leading provider of cancer genetics testing services, announced today that Douglas M. VanOort, 53 years old, has joined the Company's Board of Directors and been appointed Executive Chairman and Interim Chief Executive Officer. The Company also reported that Mr. VanOort has made a $500,000 investment into NeoGenomics by purchasing 625,000 shares of common stock at a purchase price of $0.80 per share.
Mr. VanOort has held executive leadership positions with several world-class Fortune 500 firms and rapidly-growing ventures during his 30-year career. He spent over 10 years in health-care services, first as Executive Vice President and Chief Financial Office of Corning Life Sciences, Inc. and then as Senior Vice President, Operations at Quest Diagnostics, Inc. At Corning Life Sciences, he helped build and engineer the spin off of two leading publically-traded NYSE life-science companies, Quest Diagnostics, Inc. and Covance, Inc, ultimately joining Quest at the time of the spin-off. During his tenure with Corning Life Sciences and then Quest, he was part of the team that successfully transformed the company into the largest independent clinical laboratory testing company in the United States, growing it from approximately $500 million in revenue in 1989 to approximately $1.5 billion in revenue in 1998. During the past 10 years, Mr. VanOort founded, invested in, and built businesses in a variety of industries. He currently serves as Operating Partner at Summer Street Capital Partners, Managing Director of Conundrum Capital Partners, and as a member of the Board of several private-equity held companies.
"It gives me great pleasure to welcome Doug VanOort to our team," said Dr. Michael Dent, founder of NeoGenomics. "His track record in o
|SOURCE NeoGenomics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved